San Diego, CA -- (SBWIRE) -- 11/30/2016 -- An investigation for investors of Puma Biotechnology Inc (NYSE:PBYI) shares over possible securities laws violations by Puma Biotechnology and certain of its directors and officers was announced.
Investors who purchased shares of Puma Biotechnology Inc (NYSE:PBYI), have certain options and should contact the Shareholders Foundation at email@example.com or call 858-779-1554.
The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Puma Biotechnology Inc (NYSE:PBYI) concerning whether certain statements regarding Puma Biotechnology's business, its prospects and its operations were materially false and misleading at the time they were made.
On November 14, 2016, news of an investigation of an open-label Phase 2 clinical trial ("CONTROL") was revealed. The investigation concerned the incidence rate of severe diarrhea (grade 3) in early stage HER2+ breast cancer patients receiving Puma Biotechnology's Neratinib drug (the "incidence rate").
Following this high incidence of approximately 40%, the CONTROL study reportedly investigated the incidence rate where the antidiarrheal prophylaxis Loperamide was dispensed.
The investigation reportedly showed a high incidence rate stayed at about 27% and that the CONTROL study was then extended to include a group of patients who were administered Loperamide and the corticosteroid Budesonide. The incidence rate reportedly did drop, but was still at 12.9%. Shares of Puma Biotechnology (NYSE:PBYI) declined on November 14, 2016 to as low as $32.72 per share.
Those who purchased shares of Puma Biotechnology Inc have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego